MedTrace Logo

Tanshinone in Polycystic Ovary Syndrome

NCT01452477 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-09-04

No results posted yet for this study

Summary

Tanshinone was originally isolated from dried roots of Salvia miltiorrhiza bunge. In Chinese medicine, this herb has been widely prescribed for several pathologies, including diabetes, acne, cardiovascular disease.It has been demonstrated that the therapeutic benefit of cryptotanshinone on prenatally androgenized rats may be mediated by its dual regulation of key molecules during both insulin signaling and androgen synthesis.The purpose of this study is to determine whether tanshinone may prove effective in eradicating Polycystic Ovary Syndrome (PCOS) symptomatology.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

tanshinone

tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.

DRUG

tanshinone placebo

placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.

Sponsors & Collaborators

  • Heilongjiang University of Chinese Medicine

    lead OTHER

Principal Investigators

  • Xiaoke Wu, docotor · The First Affliated Hospital,Heilongjiang University of Chinese Medicine .

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
36 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-12-31
Completion
2014-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01452477 on ClinicalTrials.gov